// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Can community pharmacy services help early identification of psoriatic arthritis? A novel proof of concept study

Pankaj Mehra - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

N/A

Early arthritis self-management sessions: does it have a role?

Muhammad S Jamal - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Rheumatology nurse specialists and corticosteroid prescribing: is it safe?

Julie Begum - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Impact of caring for someone with a rare rheumatic condition: views from patients and informal carers

Janice Mooney - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anti-neutrophil cytoplasmic antibody-associated vasculitis

N/A

How effective are interventions targeting patient activation in people with long-term physical conditions? A systematic review

Bethan Jones - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A physiotherapy-led in-patient intensive rehabilitation programme for ankylosing spondylitis: follow-up outcomes

Caroline Clarke - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

N/A

How good are healthcare professionals at identifying BMI?

Harriet Penney - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Developmentof a booklet providing information to schools and parents on how to support apupil with JIA

Anne H Gilbert - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Switching to biosimilar rituximab: a real world study

Muhammad K Nisar - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Rituximab

Comparison of cell populations between juvenile idiopathic arthritis (JIA) and camptodactyly-arthropathy-coxa vara-pericarditis syndrome (CACP) patients

Laetitia Jervis - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Camptodactyly-arthropathy-coxa vara-pericarditis syndrome

N/A

Magnetic resonance imaging and the assessment of disease activity in juvenile idiopathic arthritis

Josh Bennett - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

The impact of juvenile idiopathic arthritis on adolescents and young adults: a qualitative study

Hema Chaplin - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Feasibility of wearable technologies in children and young people with juvenile idiopathic arthritis

Victoria Harbottle - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Experience of illness uncertainty in parents of children with juvenile idiopathic arthritis

Kathleen Mulligan - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Proteomic analysis to define predictors of treatment response in rheumatoid arthritis patients

Stephanie F Ling - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

The JAK1-selective inhibitor filgotinib reverses the disease-associated transcriptional profile in the blood of patients with active rheumatoid arthritis

Peter Taylor - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Filgotinib

In vivo assessment of prevention of lung fibrosis using the pan-PPAR agonist lanifibranor in the TbRIIDk-fib mouse model of systemic sclerosis

Emma Derrett-Smith - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

Lanifibranor

Prolyl 3-hydroxylase 2 is a candidate gene in scleroderma involved in collagen synthesis and fibrosis

Bahja Ahmed Abdi - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

Alora

Anti-CD3 and p38 inhibition as a potential novel combination therapy acting to boost CD8 regulatory T cells whilst minimising inflammatory cytokine release in rheumatoid arthritis

Anna Zarafov - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Adalimumab

Symptoms in first degree relatives of patients with rheumatoid arthritis: evaluation of data from the symptoms in persons at risk of rheumatoid arthritis questionnaire

Ruth E Costello - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Copyright © 2026. QuantiNova All rights reserved